Results 21 to 30 of about 822,808 (285)

Mitochondria Dysfunction at the Heart of Viral Myocarditis: Mechanistic Insights and Therapeutic Implications

Viruses, 2023
The myocardium/heart is the most mitochondria-rich tissue in the human body with mitochondria comprising approximately 30% of total cardiomyocyte volume.
Y. Mohamud, Boaz Li, A. Bahreyni, Honglin Luo   +3 more
semanticscholar   +1 more source

Reconstituted Extracellular Vesicles from Human Platelets Decrease Viral Myocarditis in Mice.

Small, 2023
Patients with viral myocarditis are at risk of sudden death and may progress to dilated cardiomyopathy (DCM). Currently, no disease-specific therapies exist to treat viral myocarditis.
Danielle J Beetler, K. A. Bruno, Molly M Watkins, Vivian Xu, Isha Chekuri, Presley Giresi, Damian N Di Florio, E. Whelan, B. Edenfield, Sierra A. Walker, A. C. Morales-Lara, Anneliese R. Hill, Angita Jain, Matthew E Auda, Logan P. Macomb, Kathryn A Shapiro, Kevin C Keegan, Joy Wolfram, A. Behfar, P. Stalboerger, A. Terzic, H. Farres, L. Cooper, D. Fairweather   +23 more
semanticscholar   +1 more source

Roles of inflammasomes in viral myocarditis

Frontiers in Cellular and Infection Microbiology, 2023
Viral myocarditis (VMC), characterized by viral infection-induced inflammation, is a life-threatening disease associated with dilated cardiomyopathy or heart failure.
Jingyu Xu, Zihao Zhou, Y. Zheng, Sai Yang, Kun Huang, Huili Li   +5 more
semanticscholar   +1 more source

Viral Myocarditis: Classification, Diagnosis, and Clinical Implications

Frontiers in Cardiovascular Medicine, 2022
Myocarditis is an inflammatory disease of the myocardium with focal or diffuse involvement. Viral infections are the most common cause of myocarditis, especially in Western countries.
F. Sozzi, E. Gherbesi, Andrea Faggiano, E. Gnan, Alessio Maruccio, M. Schiavone, L. Iacuzio, S. Carugo   +7 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitor-Induced Myocarditis vs. COVID-19 Vaccine-Induced Myocarditis—Same or Different?

Life, 2022
Immune checkpoint inhibitor (ICI) and coronavirus disease 2019 (COVID-19) vaccine-induced myocarditis possibly share common mechanisms secondary to overactivation of the immune system.
Lior Zornitzki, Ofer Havakuk, Zach Rozenbaum, Dana Viskin, Yaron Arbel, Nir Flint, Joshua Arnold, Barliz Waissengein, Ido Wolf, Shmuel Banai, Yan Topilsky, Michal Laufer-Perl   +11 more
doaj   +1 more source

Neutrophil inhibition improves acute inflammation in a murine model of viral myocarditis

Cardiovascular Research, 2022
Aims Viral myocarditis (VM) is an inflammatory pathology of the myocardium triggered by a viral infection that may cause sudden death or heart failure (HF), especially in the younger population.
P. Carai, Laura Florit González, Stijn Van Bruggen, V. Spalart, Daria De Giorgio, Nadéche Geuens, K. Martinod, E. Jones, S. Heymans   +8 more
semanticscholar   +1 more source

Viral Myocarditis: Clinical and Paraclinical Diagnosis [PDF]

Modern Medicine, 2020
Myocarditis is an inflammatory disease of the myocardium, that can be produced by a multitude of infectious or noninfectious agents. The incidence rate of the disease is between 10 to 22 per 100,000 individuals.
Gabriela CEOBANU, Gina GHEORGHE, Ovidiu BRATU, Nicolae BACALBASA, Mihaela C. OLARIU, Tiberiu P. Neagu, Camelia DIACONU   +6 more
doaj   +1 more source

Treatment Trends of Myocarditis with Coxsackievirus B3 infection

Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2020
Viral myocarditis occurred after viral invasion of the cardiocytes and followed by the releasing of viral particles and inflammatory cells. Acute viral myocarditis is relatively common phase of the disease cured spontaneously in some cases or leading to
Dalya Basil Hanna, Ghaith Ali Jasim, Arwa Mujahid Abdullah Al-Shuwaikh   +2 more
doaj   +1 more source

Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis

ESC Heart Failure, 2022
The acute phase of a coxsackievirus 3 (CVB3)‐induced myocarditis involves direct toxic cardiac effects and the systemic activation of the immune system, including the cardiosplenic axis.
K. Pappritz, Jie Lin, M. El-Shafeey, H. Fechner, U. Kühl, A. Alogna, F. Spillmann, A. Elsanhoury, R. Schulz, C. Tschöpe, S. Van Linthout   +10 more
semanticscholar   +1 more source

Dapagliflozin Alleviates Coxsackievirus B3-induced Acute Viral Myocarditis by Regulating the Macrophage Polarization Through Stat3-related Pathways

Inflammation, 2022
Viral myocarditis (VMC), which is most prevalently caused by Coxsackievirus B3 (CVB3) infection, is a serious clinical condition characterized by cardiac inflammation. Dapagliflozin, a kind of sodium glucose co-transporters 2(SGLT-2) inhibitor, exhibited
P. Yan, Xiaoning Song, Joanne Tran, Run-hua Zhou, Xinran Cao, Gang Zhao, Haitao Yuan   +6 more
semanticscholar   +1 more source